Artificial Pancreas Race Intensifies Between These 3 Medtech Firms
Expected to start late this year, the International Diabetes Closed-Loop Trial (IDCLT) will combine technologies from three companies that are looking to make major strides in type 1 diabetes therapy via commercialization of a true artificial pancreas: Tandem Diabetes Care, Dexcom, and TypeZero Technologies.
The trial—sponsored by the University of Virginia and funded by NIH—will include 240 people between the ages of 14 and 75 who have type 1 diabetes.
IDCLT is set up as “a pivotal trial of a closed-loop control-to-range system and includes seven institutions in the United States and three in Europe led by the University of Virginia,” Boris Kovatchev, PhD, director of the Center for Diabetes Technology at the University of Virginia and principal investigator of IDCLT, said in a statement.
The trial—sponsored by the University of Virginia and funded by NIH—will include 240 people between the ages of 14 and 75 who have type 1 diabetes.
IDCLT is set up as “a pivotal trial of a closed-loop control-to-range system and includes seven institutions in the United States and three in Europe led by the University of Virginia,” Boris Kovatchev, PhD, director of the Center for Diabetes Technology at the University of Virginia and principal investigator of IDCLT, said in a statement.